Last reviewed · How we verify
IPSRT plus quetiapine
IPSRT plus quetiapine is a Small molecule drug developed by Holly Swartz. It is currently FDA-approved. Also known as: IPSRT-QUE.
IPSRT (Interpersonal and Social Rhythm Therapy) was studied in combination with quetiapine, a serotonin 2a receptor antagonist, for the treatment of bipolar disorder and depression. Quetiapine is a small molecule drug that acts as an antagonist at the 5-hydroxytryptamine receptor 2A.
At a glance
| Generic name | IPSRT plus quetiapine |
|---|---|
| Also known as | IPSRT-QUE |
| Sponsor | Holly Swartz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPSRT plus quetiapine CI brief — competitive landscape report
- IPSRT plus quetiapine updates RSS · CI watch RSS
- Holly Swartz portfolio CI
Frequently asked questions about IPSRT plus quetiapine
What is IPSRT plus quetiapine?
Who makes IPSRT plus quetiapine?
Is IPSRT plus quetiapine also known as anything else?
What development phase is IPSRT plus quetiapine in?
Related
- Manufacturer: Holly Swartz — full pipeline
- Also known as: IPSRT-QUE
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing